Professional virtual currency information station welcome
We have been making efforts.
4 Articles

Tags :R&D investment

Interpretation Of Maiwei Biotech's 2025 Annual Report: Revenue Increases, Losses Decrease, R&D Investment Is High, And There Are Many Varieties

On March 24, Maiwei Biotech announced its 2025 annual report. The company's operating income was 663 million yuan, a year-on-year increase of 231.6%; the net profit attributable to the parent company increased from a loss of 1.04 billion yuan in the same period last year to a loss of 969 million yuan.

Shengshi Technology Has Established A 200 Million Wholly-owned Subsidiary. The Investment Is Risky And The Performance Decline Needs To Be Improved.-Lijin Finance

Shengshi Technology Has Established A 200 Million Wholly-owned Subsidiary. The Investment Is Risky And The Performance Decline Needs To Be Improved.

Recently, Shengshi Technology (002990) announced that the company held a board meeting on February 13 to review and approve the proposal to establish a wholly-owned subsidiary, Shenzhen Shengxin Investment Co., Ltd., with a registered capital of 200 million yuan, and the company holds 100% of its equity.

Sign In

Forgot Password

Sign Up